Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 706321 plus ustekinumab in Crohn's disease
2024-512756-38-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BI 706321 + ustekinumab with Placebo + ustekinumab (2 arms). Primary endpoint: Absolute change from baseline in SES-CD at week 12. Started Jul 2024; status: completed.
02
Drugs
bi 706321
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-512756-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512756-38-00.